WuXi AppTec took part in the cancer test developer's latest round through WuXi NextCode and 6 Dimensions Capital, taking its total funding to more than $1.6bn.
US-based cancer test developer Grail secured $300m yesterday in an oversubscribed series C round co-led by 6 Dimensions Capital, the healthcare investment firm co-founded by pharmaceutical group WuXi AppTec.
The round, which was co-led by healthcare investment group Ally Bridge and hedge fund manager Hillhouse Capital, also featured WuXi AppTec’s genomic information subsidiary, WuXi NextCode.
Blue Pool Capital, China Merchant Securities International, CRF Investment, HuangPu River Capital, ICBC International and Sequoia Capital China filled out the investor consortium.
Spun off…